August 25, 2026European Journal of Heart Failure
Efficacy of digitoxin over time in patients with heart failure and reduced ejection fraction: further analysis of DIGIT-HF
No abstract yet
We only have this paper's title and publication details.
Read it at the sourceAsk about this paper
Answers are grounded in this paper and cite their sources.
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“If you have to add another medication, I think you have to really specify which patients would likely profit, but overall, I think, it's important that we have a clearly positive signal in the data.”
“Therefore, the four pillars of treatment—ARNI, beta-blockers, MRA, and SGLT2 inhibitors—will continue as clear first-line therapy, but digitoxin seems to be a great option for those patients who remain symptomatic despite being on the four pillars.”
“Although encouraging, the apparent 18% risk reduction in DIGIT-HF may not survive replication under adequately powered conditions.”
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Bavendiek et al. (2026) studied this question.